Diana Roettger, PhD, and Olga Kubassova, PhD[email protected]MRIAdvanced imaging offers insight into targeted therapiesMajor breakthroughs are emerging in the development of targeted therapies that use the body's own immune system to attack cancer cells. But traditional methods of measuring the success of drug candidates are slow and expensive. Could advanced imaging help? Diana Roettger, PhD, and Olga Kubassova, PhD, of the Image Analysis Group offer a perspective.February 5, 2019Page 1 of 1Top StoriesAIU.S. FDA may need to clarify SaMD validation standardsIn a video interview, a Dana-Farber Cancer Institute expert describes what the "rigor spectrum" is in validation study designs.Molecular ImagingPSMA-PET/CT may replace NaF-PET/CT in advanced prostate cancerWomens ImagingPreop breast MRI improves surgical planning, but use disparities remainWomens ImagingFIGO classification from MRI leads to moderate agreement among radsSponsor ContentRegister Now: Breaking Barriers in Breast Imaging Webinar